Cargando…
Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
Autores principales: | Ucciferri, Claudio, Barone, Mirko, Vecchiet, Jacopo, Falasca, Katia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340237/ https://www.ncbi.nlm.nih.gov/pubmed/32670526 http://dx.doi.org/10.4084/MJHID.2020.048 |
Ejemplares similares
-
Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022) -
Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023) -
Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018) -
Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016) -
Role of monoclonal antibody drugs in the treatment of COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)